14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Use of nasal high flow oxygen during acute respiratory failure

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nasal high flow (NHF) has gained popularity among intensivists to manage patients with acute respiratory failure. An important literature has accompanied this evolution. In this review, an international panel of experts assessed potential benefits of NHF in different areas of acute respiratory failure management. Analyses of the physiological effects of NHF indicate flow-dependent improvement in various respiratory function parameters. These beneficial effects allow some patients with severe acute hypoxemic respiratory failure to avoid intubation and improve their outcome. They require close monitoring to not delay intubation. Such a delay may worsen outcome. The ROX index may help clinicians decide when to intubate. In immunocompromised patients, NHF reduces the need for intubation but does not impact mortality. Beneficial physiological effects of NHF have also been reported in patients with chronic respiratory failure, suggesting a possible indication in acute hypercapnic respiratory failure. When intubation is required, NHF can be used to pre-oxygenate patients either alone or in combination with non-invasive ventilation (NIV). Similarly, NHF reduces reintubation alone in low-risk patients and in combination with NIV in high-risk patients. NHF may be used in the emergency department in patients who would not be offered intubation and can be better tolerated than NIV.

          Electronic supplementary material

          The online version of this article (10.1007/s00134-020-06228-7) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references71

          • Record: found
          • Abstract: found
          • Article: not found

          An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy

          Rationale: One important concern during high-flow nasal cannula (HFNC) therapy in patients with acute hypoxemic respiratory failure is to not delay intubation. Objectives: To validate the diagnostic accuracy of an index (termed ROX and defined as the ratio of oxygen saturation as measured by pulse oximetry/FiO2 to respiratory rate) for determining HFNC outcome (need or not for intubation). Methods: This was a 2-year multicenter prospective observational cohort study including patients with pneumonia treated with HFNC. Identification was through Cox proportional hazards modeling of ROX association with HFNC outcome. The most specific cutoff of the ROX index to predict HFNC failure and success was assessed. Measurements and Main Results: Among the 191 patients treated with HFNC in the validation cohort, 68 (35.6%) required intubation. The prediction accuracy of the ROX index increased over time (area under the receiver operating characteristic curve: 2 h, 0.679; 6 h, 0.703; 12 h, 0.759). ROX greater than or equal to 4.88 measured at 2 (hazard ratio, 0.434; 95% confidence interval, 0.264-0.715; P = 0.001), 6 (hazard ratio, 0.304; 95% confidence interval, 0.182-0.509; P < 0.001), or 12 hours (hazard ratio, 0.291; 95% confidence interval, 0.161-0.524; P < 0.001) after HFNC initiation was consistently associated with a lower risk for intubation. A ROX less than 2.85, less than 3.47, and less than 3.85 at 2, 6, and 12 hours of HFNC initiation, respectively, were predictors of HFNC failure. Patients who failed presented a lower increase in the values of the ROX index over the 12 hours. Among components of the index, oxygen saturation as measured by pulse oximetry/FiO2 had a greater weight than respiratory rate. Conclusions: In patients with pneumonia with acute respiratory failure treated with HFNC, ROX is an index that can help identify those patients with low and those with high risk for intubation. Clinical trial registered with www.clinicaltrials.gov (NCT02845128).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.

            Intubation in patients with respiratory failure can be avoided by high-flow nasal cannula (HFNC) use. However, it is unclear whether waiting until HFNC fails, which would delay intubation, has adverse effects. The present retrospective observational study assessed overall ICU mortality and other hospital outcomes of patients who received HFNC therapy that failed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure.

              High-flow nasal cannula (HFNC) improves the clinical outcomes of nonintubated patients with acute hypoxemic respiratory failure (AHRF).
                Bookmark

                Author and article information

                Contributors
                jean-damien.ricard@aphp.fr
                Journal
                Intensive Care Med
                Intensive Care Med
                Intensive Care Medicine
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0342-4642
                1432-1238
                8 September 2020
                : 1-10
                Affiliations
                [1 ]GRID grid.414205.6, ISNI 0000 0001 0273 556X, Medico-surgical ICU, Assistance Publique - Hôpitaux de Paris, DMU ESPRIT, Médecine Intensive Réanimation, , Hôpital Louis Mourier, ; 92700 Colombes, France
                [2 ]Université de Paris, IAME, U1137, Inserm, 75018 Paris, France
                [3 ]GRID grid.7080.f, Critical Care Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, , Universitat Autònoma de Barcelona, ; Barcelona, Spain
                [4 ]GRID grid.413448.e, ISNI 0000 0000 9314 1427, Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, ; Madrid, Spain
                [5 ]GRID grid.50550.35, ISNI 0000 0001 2175 4109, Medical ICU Saint Louis Hospital, APHP, ; Paris, France
                [6 ]GRID grid.415184.d, ISNI 0000 0004 0614 0266, Critical Care Research Group, , The Prince Charles Hospital, ; Chermside, Australia
                [7 ]GRID grid.1003.2, ISNI 0000 0000 9320 7537, University of Queensland, ; Brisbane, QLD Australia
                [8 ]GRID grid.9647.c, ISNI 0000 0004 7669 9786, Department of Respiratory Medicine, , University of Leipzig, ; Liebigstraße 20, 04103 Leipzig, Germany
                [9 ]Klinikum Emden, Bolardusstrasse 20, 26721 Emden, Germany
                [10 ]GRID grid.9654.e, ISNI 0000 0004 0372 3343, School of Medicine, , University of Auckland, ; Auckland, New Zealand
                [11 ]GRID grid.414055.1, ISNI 0000 0000 9027 2851, Department of Emergency Medicine, , Auckland City Hospital, ; Auckland, New Zealand
                [12 ]GRID grid.267370.7, ISNI 0000 0004 0533 4667, Department of Internal Medicine, Ulsan University Hospital, , University of Ulsan College of Medicine, ; Ulsan, Korea
                [13 ]GRID grid.23856.3a, ISNI 0000 0004 1936 8390, Quebec Heart and Lung Institute, , Laval University, ; Québec City, QC Canada
                [14 ]GRID grid.412311.4, Department of Clinical, Integrated, and Experimental Medicine (DIMES), Respiratory and Critical Care, , Sant’Orsola Malpighi Hospital, ; Bologna, Italy
                [15 ]GRID grid.10223.32, ISNI 0000 0004 1937 0490, Division of Respiratory Diseases and Tuberculosis, Department of Medicine, Faculty of Medicine Siriraj Hospital, , Mahidol University, ; Bangkok, Thailand
                [16 ]GRID grid.415967.8, ISNI 0000 0000 9965 1030, Department of Respiratory Medicine, St James’s University Hospital, , Leeds Teaching Hospital NHS Trust, ; Leeds, UK
                [17 ]GRID grid.9909.9, ISNI 0000 0004 1936 8403, Leeds Institute for Medical Research, , University of Leeds, ; Leeds, UK
                [18 ]GRID grid.457377.5, Saint Eloi ICU, , Montpellier University Hospital and PhyMedExp, INSERM, CNRS, ; 34000 Montpellier, France
                [19 ]GRID grid.413514.6, ISNI 0000 0004 1795 0563, Intensive Care Medicine, , University Hospital Virgen de la Salud, ; Toledo, Spain
                Author information
                http://orcid.org/0000-0003-1828-2299
                Article
                6228
                10.1007/s00134-020-06228-7
                7478440
                32901374
                cb2a9bed-0acf-4dbe-98d5-3f2b1d5602dc
                © Springer-Verlag GmbH Germany, part of Springer Nature 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 12 May 2020
                : 21 August 2020
                Categories
                Narrative Review

                Emergency medicine & Trauma
                acute respiratory failure,ards,intubation,high flow oxygen,nasal canula,palliative care

                Comments

                Comment on this article